Exploring the Role of a Novel HPV16-Targeted Cancer T-cell Stimulating Immunotherapy (TSI) (Versamune HPV) for Human Papilloma Virus (HPV) Positive Head and Neck Cancer (HNSCC) - Episode 3
Navigating Treatment for HPV-Positive HNSCC Patients
Panelists discuss how, HPV+ head and neck cancer treatment typically follows NCCN guidelines: primary therapy includes surgery and/or chemoradiation based on staging. Immunotherapy like pembrolizumab is increasingly used, especially for recurrent/metastatic disease. Prognosis is generally better than HPV- cases.
Video Player is loading.
Video content above is prompted by the following:
- Navigating Treatment for HPV+ Patients
- What are the current treatment protocols for patients with HPV+ head and neck cancer?
- SITC Guidelines; NCCN guidelines
- How are emerging therapies (such as immunotherapy or targeted therapy) being used in the treatment of HPV+ head and neck cancer?
Related Content:
